Colchicine, an ancient treatment for gout, has been approved by the US Food and Drug Administration (FDA) for treating vascular inflammation present in patients with heart disease. The therapy, now produced by Agepha Pharma, is combined with a statin and reduces risk of serious cardiovascular events like stroke or heart attack.
According to Kevin Dunleavy, “The approval is backed by a trial of 5,522 patients with chronic coronary disease who were already taking high-intensity statins. Lodoco was found to reduce the risk of stroke and cardiovascular death by 31% compared to placebo.”
To read more, click here.
(Source: Fierce Pharma, June 20th, 2023)